Merck & Co Financial Statements (MRK)
|
|
|
|
Report date
|
|
|
25.02.2021 |
25.02.2022 |
24.02.2023 |
31.12.2023 |
11.04.2024 |
|
06.11.2024 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
41 518 |
48 704 |
59 283 |
59 871 |
60 115 |
|
63 218 |
|
Operating Income, bln rub |
|
|
6 076 |
13 703 |
19 399 |
2 982 |
2 954 |
|
15 799 |
|
EBITDA, bln rub |
? |
|
10 180 |
17 899 |
21 315 |
6 854 |
6 907 |
|
17 655 |
|
Net profit, bln rub |
? |
|
7 067 |
13 049 |
14 519 |
365.0 |
365.0 |
|
12 148 |
|
|
OCF, bln rub |
? |
|
10 253 |
14 109 |
19 095 |
13 006 |
13 006 |
|
18 264 |
|
CAPEX, bln rub |
? |
|
4 684 |
4 448 |
4 388 |
3 863 |
3 863 |
|
3 424 |
|
FCF, bln rub |
? |
|
5 569 |
9 661 |
14 707 |
9 143 |
9 143 |
|
14 840 |
|
Dividend payout, bln rub
|
|
|
6 215 |
6 610 |
7 012 |
7 445 |
7 445 |
|
7 741 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
87.9% |
50.7% |
48.3% |
2 040% |
2 040% |
|
63.7% |
|
|
OPEX, bln rub |
|
|
22 352 |
21 879 |
23 590 |
40 912 |
43 989 |
|
32 995 |
|
Cost of production, bln rub |
|
|
13 618 |
13 626 |
17 411 |
15 977 |
16 126 |
|
14 994 |
|
R&D, bln rub |
|
|
13 397 |
12 245 |
13 548 |
30 530 |
30 531 |
|
22 343 |
|
Interest expenses, bln rub |
|
|
831.0 |
806.0 |
962.0 |
1 146 |
1 146 |
|
1 253 |
|
|
Assets, bln rub |
|
|
91 588 |
105 694 |
109 160 |
106 675 |
106 675 |
|
103 953 |
|
Net Assets, bln rub |
? |
|
25 317 |
38 184 |
45 991 |
37 581 |
37 581 |
|
44 502 |
|
Debt, bln rub |
|
|
31 791 |
33 102 |
30 691 |
36 268 |
36 268 |
|
38 131 |
|
Cash, bln rub |
|
|
8 062 |
8 096 |
13 192 |
7 161 |
7 093 |
|
14 593 |
|
Net debt, bln rub |
|
|
23 729 |
25 006 |
17 499 |
29 107 |
29 175 |
|
23 538 |
|
|
Ordinary share price, rub |
|
|
78.0 |
76.6 |
111.0 |
109.0 |
109.0 |
|
102.9 |
|
Number of ordinary shares, mln |
|
|
2 530 |
2 530 |
2 532 |
2 537 |
2 607 |
|
2 532 |
|
|
Market cap, bln rub |
|
|
197 340 |
193 899 |
280 925 |
276 584 |
284 231 |
|
260 470 |
|
EV, bln rub |
? |
|
221 069 |
218 905 |
298 424 |
305 691 |
313 406 |
|
284 008 |
|
Book value, bln rub |
|
|
-9 525 |
-6 013 |
4 518 |
-1 627 |
-1 627 |
|
5 795 |
|
|
EPS, rub |
? |
|
2.79 |
5.16 |
5.73 |
0.14 |
0.14 |
|
4.80 |
|
FCF/share, rub |
|
|
2.20 |
3.82 |
5.81 |
3.60 |
3.51 |
|
5.86 |
|
BV/share, rub |
|
|
-3.76 |
-2.38 |
1.78 |
-0.64 |
-0.62 |
|
2.29 |
|
|
EBITDA margin, % |
? |
|
24.5% |
36.8% |
36.0% |
11.4% |
11.5% |
|
27.9% |
|
Net margin, % |
? |
|
17.0% |
26.8% |
24.5% |
0.61% |
0.61% |
|
19.2% |
|
FCF yield, % |
? |
|
2.82% |
4.98% |
5.24% |
3.31% |
3.22% |
|
5.70% |
|
ROE, % |
? |
|
27.9% |
34.2% |
31.6% |
0.97% |
0.97% |
|
27.3% |
|
ROA, % |
? |
|
7.72% |
12.3% |
13.3% |
0.34% |
0.34% |
|
11.7% |
|
|
P/E |
? |
|
27.9 |
14.9 |
19.3 |
757.8 |
778.7 |
|
21.4 |
|
P/FCF |
|
|
35.4 |
20.1 |
19.1 |
30.3 |
31.1 |
|
17.6 |
|
P/S |
? |
|
4.75 |
3.98 |
4.74 |
4.62 |
4.73 |
|
4.12 |
|
P/BV |
? |
|
-20.7 |
-32.2 |
62.2 |
-170.0 |
-174.7 |
|
44.9 |
|
EV/EBITDA |
? |
|
21.7 |
12.2 |
14.0 |
44.6 |
45.4 |
|
16.1 |
|
Debt/EBITDA |
|
|
2.33 |
1.40 |
0.82 |
4.25 |
4.22 |
|
1.33 |
|
|
R&D/CAPEX, % |
|
|
286.0% |
275.3% |
308.8% |
790.3% |
790.3% |
|
652.5% |
|
|
CAPEX/Revenue, % |
|
|
11.3% |
9.13% |
7.40% |
6.45% |
6.43% |
|
5.42% |
|
| Merck & Co shareholders |
